

What is claimed is:

1. A diagnostic marker for cancer comprising Ovr107.
2. The diagnostic marker of claim 1 where Ovr107 comprises SEQ ID NO:1.
3. A method for diagnosing the presence of cancer in a patient comprising:
- (a) determining levels of Ovr107 in cells, tissues or bodily fluids in a patient; and
 - (b) comparing the determined levels of Ovr107 with levels of Ovr107 in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of Ovr107 in said patient versus normal human control is associated with the presence of cancer.
4. A method of diagnosing metastases of cancer in a patient comprising:
- (a) identifying a patient having cancer that is not known to have metastasized;
 - (b) determining Ovr107 levels in a sample of cells, tissues, or bodily fluid from said patient; and
 - (c) comparing the determined Ovr107 levels with levels of Ovr107 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined Ovr107 levels in the patient versus the normal human control is associated with a cancer which has metastasized.
5. A method of staging cancer in a patient having cancer comprising:
- (a) identifying a patient having cancer;
 - (b) determining Ovr107 levels in a sample of cells, tissue, or bodily fluid from said patient; and
 - (c) comparing determined Ovr107 levels with levels of Ovr107 in cells, tissues, or bodily fluid of a normal human

control, wherein an increase in determined Ovr107 levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined Ovr107 levels is associated with a cancer which is
5 regressing or in remission.

6. A method of monitoring cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having cancer that is not known to have metastasized;

10 (b) periodically determining levels of Ovr107 in samples of cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Ovr107 levels with levels of Ovr107 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the
15 periodically determined Ovr107 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

7. A method of monitoring a change in stage of cancer in a patient comprising:

20 (a) identifying a patient having cancer;

(b) periodically determining levels of Ovr107 in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Ovr107 levels with levels of Ovr107 in cells, tissues, or bodily fluid of
25 a normal human control, wherein an increase in any one of the periodically determined Ovr107 levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

30 8. A method of identifying potential therapeutic agents for use in imaging and treating cancer comprising screening molecules for an ability to bind to Ovr107 wherein the ability

09717833-112100

of a molecule to bind to Ovr107 is indicative of the molecule being useful in imaging and treating cancer.

9. An antibody which specifically binds Ovr107.
- 5 10. A method of imaging cancer in a patient comprising administering to the patient the antibody of claim 9.
11. The method of claim 10 wherein said antibody is labeled with paramagnetic ions or a radioisotope.
- 10 12. A method of treating cancer in a patient comprising administering to the patient the antibody of claim 9.
13. The method of claim 12 wherein the antibody is conjugated to a cytotoxic agent.
- 15 14. A method of treating cancer in a patient comprising administering to the patient a molecule which downregulates expression or activity of Ovr107.
- 20 15. A method of inducing an immune response against a target cell expressing Ovr107 comprising delivering to a human patient an immunogenically stimulatory amount of an Ovr107 protein so that an immune response is mounted against the target cell.
16. A vaccine for treating cancer comprising Ovr107.

09717883 112100